Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

10.85 +1.91 (+21.31%)

Streaming Delayed Price Updated: 3:27 PM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why

February 27, 2026

Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about...

Via StockStory

Topics Economy Stocks

1 Russell 2000 Stock Worth Investigating and 2 We Avoid

February 26, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

1 Volatile Stock for Long-Term Investors and 2 Facing Challenges

February 18, 2026

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Via StockStory

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

February 17, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Tuesday's pre-market session: top gainers and losers ↗

February 17, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗

February 17, 2026

Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds ↗

February 16, 2026

Wall Street has grown increasingly optimistic ahead of the readout, with analysts pointing to a potential blockbuster opportunity in wet AMD.

Via Stocktwits

Wondering what's happening in today's after-hours session? ↗

February 16, 2026

Via Chartmill

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

February 16, 2026

In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly...

Via MarketMinute

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...

Via MarketMinute

Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates

February 05, 2026

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 22.4% year on year to $13.25 million. Its...

Via StockStory

Topics Artificial Intelligence

A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack

January 26, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Ocular Therapeutix...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Cash-Burning Stocks We’re Skeptical Of

January 19, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...

Via StockStory

Topics Bankruptcy

1 Healthcare Stock to Consider Right Now and 2 We Find Risky

January 15, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and...

Via StockStory

Topics Stocks

What's going on in today's pre-market session ↗

January 15, 2026

Via Chartmill

Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗

January 15, 2026

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

Via Stocktwits

3 Reasons OCUL is Risky and 1 Stock to Buy Instead

January 13, 2026

Over the last six months, Ocular Therapeutix’s shares have sunk to $10.44, producing a disappointing 7.4% loss - a stark contrast to the S&P 500’s 11.3% gain. This might have investors contemplating...

Via StockStory

Topics Bankruptcy Stocks

1 Unprofitable Stock with Impressive Fundamentals and 2 We Find Risky

January 07, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital...

Via StockStory

3 Stocks Under $50 with Questionable Fundamentals

January 05, 2026

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

3 of Wall Street’s Favorite Stocks Walking a Fine Line

January 04, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Topics Economy Supply Chain

Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales

January 02, 2026

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q3 CY2025 results topping the market’s revenue expectations, but sales fell by 5.7% year on year to $14.54 million. Its...

Via StockStory

Topics Artificial Intelligence

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug ↗

December 08, 2025

Ocular Therapeutix Inc (NASDAQ: OCUL) stock surged after announcing plans to expedite FDA submission for its wet AMD treatment.

Via Benzinga

OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q3 2025 Results with Narrower-Than-Expected Loss ↗

November 04, 2025

OCULAR THERAPEUTIX reported mixed Q3 2025 results, with a slight revenue miss but a narrower-than-expected loss. The company highlighted progress in its AXPAXLI clinical pipeline.

Via Chartmill

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

October 08, 2025

Via Benzinga

Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts ↗

October 01, 2025

Via Benzinga

This Broadcom Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

September 15, 2025

Via Benzinga

OCUL Sales Drop 18% ↗

August 05, 2025

Via The Motley Fool

OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q2 2025 Earnings Amid Clinical Progress ↗

August 05, 2025

OCULAR THERAPEUTIX reported mixed Q2 2025 results, missing revenue and EPS estimates. Stock dipped 6% pre-market but gained 28.5% over the past month. Progress in AXPAXLI™ SOL trials for wet AMD...

Via Chartmill

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.